We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test to Assess Nerve Damage Could Also Detect Alzheimer’s Years Before Onset

By LabMedica International staff writers
Posted on 28 Jun 2022
Print article
Image: Researchers have discovered in the blood a potential biomarker for nerve damage (Photo courtesy of DZNE)
Image: Researchers have discovered in the blood a potential biomarker for nerve damage (Photo courtesy of DZNE)

Researchers have identified a protein in the blood that may indicate the degradation of neural connections years before the onset of dementia symptoms. If these findings are confirmed, recording this protein called “beta-synuclein” could contribute to the early detection of Alzheimer’s disease and possibly also help to assess nerve damage resulting from stroke or traumatic brain injury.

The evidence is based on studies of 84 adults, including 61 people with Down syndrome (also known as “trisomy 21”), conducted by researchers from the German Center for Neurodegenerative Diseases (DZNE, Göttingen, Germany) and Ulm University Hospital (Ulm, Germany).

“Our data suggest that levels of beta-synuclein in the blood rise already in the early stages of Alzheimer’s disease and that this is related to the breakdown of neural connections, so-called synapses,” explained Dr. Patrick Öckl, research group leader at DZNE’s Ulm site and at the Department of Neurology at Ulm University Hospital. “So here we have a potential biomarker that could help detect incipient dementia at an early phase – presumably more than 10 years before symptoms become manifest.” At present, Alzheimer’s disease is diagnosed and treated far too late, the scientist noted: “By then, the brain is already massively damaged. We need to start earlier to increase the chances of being able to effectively combat the disease. Beta-synuclein could open up a possibility for this. However, further studies are still needed to confirm our findings.”

“People with Down syndrome are affected by a genetically determined developmental disorder of the brain, which usually results in an impairment of intellectual abilities. In addition, their genome exacerbates molecular processes that are involved in the development of Alzheimer’s. Down syndrome is therefore associated with an inherited form of Alzheimer’s disease with an early onset of symptoms. Usually, this happens beyond the age of 40,” said Prof. Johannes Levin, neurologist at DZNE’s Munich site and head of the outpatient clinic at LMU Klinikum München for individuals with Down syndrome and cognitive disorders. “From the study of Down syndrome, we can learn quite a bit about dementia. We assume that the processes that occur here in a particularly pronounced way also happen in individuals who have Alzheimer’s but no Down syndrome.”

If further studies confirm the current findings, various applications could be considered for the beta-synuclein marker: “For drug studies on Alzheimer’s disease, a synaptic blood marker would be very helpful to record treatment effects, that is, to determine what an experimental compound does in the brain. This would usefully complement the picture provided by the already established markers,” said Prof. Markus Otto, head of the Department of Neurology at University Medicine Halle, who also played a significant role in the current studies. “I see another application in dementia prevention and early detection. The possibility to measure beta-synuclein in blood is much more convenient for patients compared with the currently used analysis of cerebrospinal fluid.”

“Considering that synapses are also lost in traumatic brain injury and stroke, the relevance of beta-synuclein is even more far-reaching. In these cases, too, the marker could help assess nerve damage and thus contribute significantly to better diagnostics and therapy,” added Otto.

Related Links:
DZNE 
Ulm University Hospital 

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
New
Microscope
M250 Series
New
Cystatin C POC Test
Cystatin C Assay

Print article
GLOBETECH PUBLISHING LLC

Channels

Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Hematology

view channel
Image: The latest FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer (Photo courtesy of PixCell)

True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

An innovative 5-part differential Complete Blood Count (CBC) analyzer with direct capillary sampling capability significantly simplifies blood sampling and minimizes the pre-analytical process.... Read more

Immunology

view channel
Image: A new test could detect the body’s adaptive immune response to viruses (Photo courtesy of 123RF)

Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form

The adaptive immune system is an incredible defense mechanism that allows the human body to identify and mount targeted responses against specific pathogens. T-Cells, a special kind of white blood cell,... Read more

Microbiology

view channel
Image: On-chip pretreatment and rapid AST based directly on positive blood cultures (Photo courtesy of Liu Yang)

Integrated Solution for Rapid AST Directly From Positive Blood Cultures to Combat Bloodstream Infection

The presence of living bacteria in the bloodstream, known as bacteremia, can lead to serious conditions like bloodstream infections (BSIs) and sepsis, which can often be fatal. Quickly prescribing the... Read more

Pathology

view channel
Image: The Mitotic Counting algorithm was trained on over 100,000 individual mitosis and across seven scanner models (Photo courtesy of Gestalt Diagnostics)

New AI Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models

A new artificial intelligence (AI) algorithm for use on one of the broadest trained environments is now available for commercial or research work. Gestalt Diagnostics (Spokane, WA, USA) has released the... Read more

Technology

view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more

Industry

view channel
Image: AACC Middle East is a two-day conference that brings the latest in laboratory medicine to the Middle East region (Photo courtesy of ADLM)

AACC Middle East 2023 to Explore Latest Trends in Clinical Pathology and Laboratory Medicine

The AACC Middle East Conference and Exposition will be held by the Association for Diagnostics & Laboratory Medicine (ADLM - formerly AACC, Washington, DC, USA) in partnership with Life Dx (Abu Dhabi,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.